# Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

Study · id `cardio:ct-nct02023879` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02023879](<https://clinicaltrials.gov/study/NCT02023879>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02023879

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 233 participants.

## Technical summary

Registry record NCT02023879. Randomized; triple masking; primary purpose treatment. Start 2013-12-16 (registry gives no type); primary completion 2014-10-27 (actual). Results posted on 2017-03-15.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 233 participants (enrolled count; ClinicalTrials.gov record NCT02023879, source copy `cardio:ctgov-nct02023879-2018-07-27`, retrieved 2026-10-31)
- Start date: 2013-12-16 (registry gives no type) (ClinicalTrials.gov record NCT02023879, source copy `cardio:ctgov-nct02023879-2018-07-27`, retrieved 2026-10-31)
- Primary completion: 2014-10-27 (actual) (ClinicalTrials.gov record NCT02023879, source copy `cardio:ctgov-nct02023879-2018-07-27`, retrieved 2026-10-31)
- Completion: 2017-06-30 (actual) (ClinicalTrials.gov record NCT02023879, source copy `cardio:ctgov-nct02023879-2018-07-27`, retrieved 2026-10-31)
- Results first posted: 2017-03-15 (ClinicalTrials.gov record NCT02023879, source copy `cardio:ctgov-nct02023879-2018-07-27`, retrieved 2026-10-31)
- Countries: United States; Australia; Belgium; Canada; Denmark; Netherlands; New Zealand; Spain (ClinicalTrials.gov record NCT02023879, source copy `cardio:ctgov-nct02023879-2018-07-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02023879-2018-07-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)
- Condition: Hypercholesterolemia
- Intervention (Drug): Alirocumab
- Intervention (Drug): Placebo (for Alirocumab)
- Intervention (Drug): Non-statin LMT
- Intervention (Other): Diet Alone
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY
- Collaborator: Regeneron Pharmaceuticals
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Alirocumab (`cardio:alirocumab`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)
- Registry lists this organization as a collaborator: Regeneron Pharmaceuticals (`cardio:org-regeneron-pharmaceuticals`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study (`cardio:pubmed-27625344`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: ad946523d875fb7ac6e0f878a61df5ae3fa514ac1eb3a823c842e6c33fc88f2f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
